血管舒缩症状市场规模、份额、成长分析（按治疗类型、按分销管道、按最终用户、按地区）- 2025 年至 2032 年行业预测

血管运动症状市场规模预计到 2023 年将达到 37.4 亿美元，从 2024 年的 40.00 亿美元增长到 2032 年的 68.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.9%。

根据市场洞察，血管舒缩症状是月经女性报告最常见的问题，主要特征是潮热、盗汗和贫血。这些症状会导致突然发烧和过度出汗，尤其是在颈部、脸部和前额。心悸的频率和强度也有很大差异，特别是在停经后的头两年，这可能是一个特别的挑战。对许多女性来说，这些令人衰弱的症状可能是永久性的，凸显了月经经验的个人方面。此外，多方​​面的神经系统症状的复杂性凸显了需要製定个人化解决方案来解决女性在不断变化的社会动态中度过这段过渡时期时所面临的独特挑战。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

血管舒缩症状市场规模（依治疗类型及复合年增长率）（2025-2032）

• 市场概览
• 雌激素
• 孕酮
• 组合
• 非处方激素
• 抗忧郁症
• 其他的

血管舒缩症状市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 药局

血管舒缩症状市场规模（依最终用户和复合年增长率划分）（2025-2032）

• 市场概览
• 医院和诊所
• 专业中心
• 其他的

血管舒缩症状市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• TherapeuticsMD（United States）
• Mithra Pharmaceuticals（Belgium）
• KaNDy Therapeutics（United Kingdom）
• Fervent Pharmaceuticals（United States）
• Astellas Pharma（Japan）
• Sojournix（United States）
• Mitsubishi Tanabe Pharma（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Pfizer Inc.（United States）
• Hikma Pharmaceuticals PLC（United Kingdom）
• Dr. Reddy's Laboratories Ltd.（India）
• AbbVie Inc.（United States）
• Endo Pharmaceuticals PLC（Ireland）
• Novartis AG（Switzerland）
• Wockhardt（India）
• Bayer AG（Germany）
• Eli Lilly and Company（United States）
• Sun Pharmaceutical Industries Ltd.（India）
• Alembic Pharmaceuticals Limited（India）
• Zydus Group（India）

结论和建议

Vasomotor Symptoms Market size was valued at USD 3.74 billion in 2023 and is poised to grow from USD 4.0 billion in 2024 to USD 6.82 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

Market insights reveal that vasomotor symptoms are the most prevalent issues reported by women during menstruation, primarily characterized by hot flashes, night sweats, and anemia. These symptoms can lead to sudden sensations of heat and excessive sweating, particularly on the neck, face, and forehead. The frequency and intensity of heart palpitations also exhibit significant variability, especially during the first two years of menopause, marking this period as particularly challenging. For many women, these debilitating symptoms may become permanent, underlining the individual aspects of menstrual experiences. Furthermore, the complexity of multidimensional neurological symptoms emphasizes the necessity for tailored solutions to address the unique challenges faced by women navigating this transitional phase amidst evolving social dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Vasomotor Symptoms market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Vasomotor Symptoms Market Segments Analysis

Global Vasomotor Symptoms Market is segmented by Therapy Type, Distribution Channel, End User and region. Based on Therapy Type, the market is segmented into Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Drug Stores. Based on End User, the market is segmented into Hospitals and Clinics, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Vasomotor Symptoms Market

Research and development (R&D) efforts and clinical trials are crucial in enhancing our comprehension of the mechanisms behind neurological symptoms, such as physiological changes and genetic mutations. This deeper insight can lead to the creation of more precise and effective therapies. As researchers delve into the complexities of neurological disorders through clinical trials, they contribute significantly to the market's strong compound annual growth rate (CAGR). These trials not only broaden the spectrum of available treatments but also stimulate market expansion by introducing groundbreaking therapeutic solutions, thereby driving advancements in the Vasomotor Symptoms market.

Restraints in the Vasomotor Symptoms Market

The Vasomotor Symptoms market faces significant constraints due to the high expenses linked with many treatment options. Market participants frequently allocate considerable resources towards developing innovative treatment strategies aimed at enhancing recovery outcomes, which consequently drives up overall costs. These hefty investments in research, development, and production lead to increased prices associated with different treatment modalities. Although these advancements offer the potential for improved patient outcomes and effectiveness of therapies, the associated higher costs create obstacles to the overall growth of the market, limiting accessibility and affordability for patients seeking relief from vasomotor symptoms.

Market Trends of the Vasomotor Symptoms Market

The vasomotor symptoms (VMS) market is experiencing notable growth, fueled by the introduction of innovative interventions and treatments that enhance awareness of these symptoms-primarily among women experiencing menopause. As awareness rises, more women are actively seeking effective relief, expanding the market significantly. Companies that specialize in pioneering new therapies or products have a distinct opportunity to gain a competitive edge, particularly if they succeed in establishing their offerings as the preferred choice among healthcare providers and patients alike. This trend suggests a vibrant, evolving marketplace characterized by heightened demand for effective VMS management solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Vasomotor Symptoms Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Estrogen
• Progesterone
• Combination
• OTC hormone
• Anti-Depressants
• Others

Global Vasomotor Symptoms Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores

Global Vasomotor Symptoms Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Specialty Centers
• Others

Global Vasomotor Symptoms Market Size & CAGR (2025-2032)

• North America (Therapy Type, Distribution Channel, End User)
  • US
  • Canada
• Europe (Therapy Type, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• TherapeuticsMD (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KaNDy Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fervent Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sojournix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo Pharmaceuticals PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations